

Jacques De Greve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3539302/publications.pdf>

Version: 2024-02-01

166
papers

26,064
citations

61977

43
h-index

7744

150
g-index

170
all docs

170
docs citations

170
times ranked

30374
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	27.0	17,395
2	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4293-4300.	1.6	1,144
3	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval. <i>Journal of Clinical Oncology</i> , 2010, 28, 2512-2519.	1.6	877
4	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1. <i>International Journal of Cancer</i> , 1999, 80, 219-230.	5.1	667
5	Phase I Study of ⁶⁸ Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 27-33.	5.0	317
6	Performance of Two Geriatric Screening Tools in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 19-26.	1.6	308
7	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. <i>Lung Cancer</i> , 2012, 76, 123-127.	2.0	260
8	miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60317.	2.5	230
9	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. <i>Annals of Oncology</i> , 2009, 20, 1596-1603.	1.2	207
10	Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 1750-1758.	1.6	201
11	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	10.7	165
12	Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. <i>Supportive Care in Cancer</i> , 2005, 13, 325-331.	2.2	162
13	The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. <i>European Journal of Cancer</i> , 2008, 44, 84-91.	2.8	145
14	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. <i>Annals of Oncology</i> , 2008, 19, 920-926.	1.2	139
15	Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. <i>Journal of Clinical Oncology</i> , 1998, 16, 411-417.	1.6	137
16	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	7.0	126
17	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 491-501.	2.9	119
18	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. <i>BMC Medicine</i> , 2012, 10, 28.	5.5	109

#	ARTICLE	IF	CITATIONS
19	Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 196-205.	1.0	99
20	Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer</i> , 2010, 46, 2206-2215.	2.8	94
21	An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5504-5504.	1.6	89
22	Cancer predisposing missense and protein truncating <i>BARD1</i> mutations in non- <i>BRCA1</i> or <i>BRCA2</i> breast cancer families. <i>Human Mutation</i> , 2010, 31, E1175-E1185.	2.5	86
23	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. <i>Oncotarget</i> , 2017, 8, 60094-60108.	1.8	85
24	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
25	De novo Alu element insertions targeted to a sequence common to the <i>BRCA1</i> and <i>BRCA2</i> genes. <i>Human Mutation</i> , 2005, 26, 284-284.	2.5	82
26	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 88, 63-69.	2.0	78
27	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
28	A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1149-1159.	2.5	72
29	The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 235-241.	1.0	72
30	Phase II Study of Preoperative Helical Tomotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 728-734.	0.8	65
31	Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008, 62, 55-61.	2.0	59
32	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. <i>BMC Cancer</i> , 2008, 8, 3.	2.6	58
33	Nutrition therapy in cachectic cancer patients. The Tight Caloric Control (TiCaCo) pilot trial. <i>Appetite</i> , 2015, 91, 298-301.	3.7	58
34	Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings—Preliminary Results. <i>Radiology</i> , 2008, 249, 471-482.	7.3	55
35	The impact of proband mediated information dissemination in families with a <i>BRCA1/2</i> gene mutation. <i>Journal of Medical Genetics</i> , 2004, 41, 23e-23.	3.2	54
36	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. <i>International Journal of Oncology</i> , 2012, 41, 1029-1035.	3.3	52

#	ARTICLE	IF	CITATIONS
37	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. <i>European Journal of Cancer</i> , 2009, 45, 146-153.	2.8	51
38	Tolerance of adjuvant letrozole outside of clinical trials. <i>Breast</i> , 2008, 17, 376-381.	2.2	49
39	The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. <i>Oncology Reports</i> , 2013, 30, 2435-2441.	2.6	49
40	The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. <i>Familial Cancer</i> , 2016, 15, 155-162.	1.9	47
41	Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 723-729.	2.3	46
42	Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. <i>Anticancer Research</i> , 2014, 34, 5517-21.	1.1	46
43	Pharmacokinetics of Intravenous Alendronate. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 385-393.	2.0	45
44	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 463-469.	2.5	44
45	Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib. <i>PLoS ONE</i> , 2013, 8, e59708.	2.5	43
46	Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. <i>Annals of Oncology</i> , 2004, 15, 59-63.	1.2	40
47	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018, 132, 391-391.	1.4	40
48	Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 40-4.	0.7	40
49	Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. <i>Biological Procedures Online</i> , 2010, 13, 1.	2.9	39
50	Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. <i>BMC Cancer</i> , 2019, 19, 313.	2.6	39
51	Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 673-681.	2.5	37
52	Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. <i>Biochemical and Biophysical Research Communications</i> , 2013, 431, 623-629.	2.1	35
53	Therapeutic potential of the vagus nerve in cancer. <i>Immunology Letters</i> , 2018, 202, 38-43.	2.5	34
54	Tumour stimulating effects of recombinant human interleukin-6. <i>Lancet</i> , The, 1994, 344, 1576-1577.	13.7	33

#	ARTICLE	IF	CITATIONS
55	Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. <i>BMC Medical Genetics</i> , 2008, 9, 83.	2.1	32
56	The added value of geriatric screening and assessment for predicting overall survival in older patients with cancer. <i>Cancer</i> , 2018, 124, 3753-3763.	4.1	31
57	Specific Congenital Malformations after Exposure to Cyclophosphamide, Epirubicin and 5-Fluorouracil during the First Trimester of Pregnancy. <i>Gynecologic and Obstetric Investigation</i> , 2011, 71, 141-144.	1.6	30
58	Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. <i>British Journal of Cancer</i> , 2001, 85, 1-8.	6.4	29
59	Moral Concerns of Different Types of Patients in Clinical <i>BRCA1/2</i> Gene Mutation Testing. <i>Journal of Clinical Oncology</i> , 1999, 17, 1595-1595.	1.6	28
60	A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3652-3659.	7.0	28
61	The genomic landscape of nonsmall cell lung carcinoma in never smokers. <i>International Journal of Cancer</i> , 2020, 146, 3207-3218.	5.1	28
62	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 671-679.	2.5	27
63	The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. <i>BMC Medical Genetics</i> , 2011, 12, 9.	2.1	27
64	Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. <i>Anticancer Research</i> , 2011, 31, 1407-9.	1.1	27
65	Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. <i>Anticancer Research</i> , 2011, 31, 4457-63.	1.1	26
66	Paraneoplastic Syndromes in Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2240-2242.	1.6	25
67	Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. <i>Oncotarget</i> , 2018, 9, 16110-16123.	1.8	25
68	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6025-6025.	1.6	25
69	Imaging of renal cell cancer with radiolabeled octreotide. <i>Nuclear Medicine Communications</i> , 1993, 14, 873-877.	1.1	23
70	Non-small-cell lung cancer with multiple paraneoplastic syndromes. <i>European Respiratory Journal</i> , 1995, 8, 1231-1234.	6.7	23
71	Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1996, 429, 59-68.	2.8	23
72	Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase quantitative polymerase chain reaction. <i>Analytical Biochemistry</i> , 2010, 398, 266-268.	2.4	23

#	ARTICLE	IF	CITATIONS
73	Savene® (dexrazoxane) use in clinical practice. Supportive Care in Cancer, 2012, 20, 1109-1112.	2.2	23
74	Frequent incidence of <i>BARD1</i> truncating mutations in germline DNA from triple-negative breast cancer patients. Clinical Genetics, 2016, 89, 336-340.	2.0	23
75	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, 2017, 8, 47154-47160.	1.8	23
76	Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death and Disease, 2016, 7, e2560-e2560.	6.3	22
77	Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, e221-e229.	2.3	22
78	Osteopathia striata with cranial sclerosis. Clinical Neurology and Neurosurgery, 1983, 85, 41-48.	1.4	21
79	Hereditary breast cancer: from bench to bedside. Current Opinion in Oncology, 2008, 20, 605-613.	2.4	20
80	Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer, 2010, 116, 241-250.	4.1	20
81	Fulvestrant (Faslodex®,) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Research and Treatment, 2008, 109, 59-65.	2.5	19
82	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Oncotarget, 2016, 7, 3068-3083.	1.8	19
83	Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 274-279.	2.8	18
84	BRCA2 founder mutation in Slovenian breast cancer families. European Journal of Human Genetics, 2002, 10, 879-882.	2.8	18
85	USP13 controls the stability of Aurora B impacting progression through the cell cycle. Oncogene, 2020, 39, 6009-6023.	5.9	18
86	Evaluation of a Comprehensive Rehabilitation Program for Post-Treatment Patients With Cancer. Oncology Nursing Forum, 2011, 38, E418-E424.	1.2	17
87	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). PLoS ONE, 2016, 11, e0147599.	2.5	17
88	A Community Peer-Volunteer Telephone Reminder Call to Increase Breast Cancer-Screening Attendance. Oncology Nursing Forum, 2010, 37, E312-E317.	1.2	16
89	CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene, 2019, 38, 5933-5941.	5.9	16
90	Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2021, 111, 272-283.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. <i>Anticancer Research</i> , 2006, 26, 611-9.	1.1	16
92	A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. <i>European Journal of Cancer</i> , 1995, 31, 2157-2163.	2.8	15
93	Alteration of Jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells. , 1999, 82, 687-693.		15
94	BRCA2 Gene Mutations in Slovenian Male Breast Cancer Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 203-209.	1.7	15
95	Systematic Detection of Pathogenic Alu Element Insertions in NGS-Based Diagnostic Screens: The BRCA1/BRCA2 Example. <i>Human Mutation</i> , 2013, 34, 785-791.	2.5	15
96	Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2021, 148, 2579-2593.	5.1	15
97	Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. <i>Clinical Genetics</i> , 2014, 85, 59-63.	2.0	14
98	Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. <i>British Journal of Cancer</i> , 2001, 85, 1592-1599.	6.4	13
99	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE3 and presented by HLA-A1. <i>International Journal of Cancer</i> , 1999, 80, 219-230.	5.1	13
100	Title is missing!. <i>Annals of Oncology</i> , 1997, 8, 691-694.	1.2	13
101	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. <i>European Respiratory Journal</i> , 2006, 29, 128-133.	6.7	12
102	Quantifying independent risk factors for failing to rescreen in a breast cancer screening program in Flanders, Belgium. <i>Preventive Medicine</i> , 2014, 69, 280-286.	3.4	12
103	How to monitor cardiac toxicity of chemotherapy: time is muscle!. <i>Heart</i> , 2014, 100, 1208-1217.	2.9	12
104	Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. <i>Advances in Therapy</i> , 2018, 35, 1945-1964.	2.9	12
105	First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5537-5537.	1.6	12
106	Lower motor neuron disease in a patient with hodgkin's disease treated with radiotherapy. <i>Clinical Neurology and Neurosurgery</i> , 1984, 86, 43-46.	1.4	11
107	Is adjuvant treatment with vinblastine effective in reducing the occurrence of distant metastasis in limited squamous cell lung cancer? A randomized study. <i>Clinical and Experimental Metastasis</i> , 1988, 6, 39-48.	3.3	11
108	Individual cancer risk as a function of current age and risk profile. <i>European Journal of Cancer Prevention</i> , 2010, 19, 485-495.	1.3	11

#	ARTICLE	IF	CITATIONS
109	Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 163-171.	1.2	11
110	The prognostic value of 3 commonly measured blood parameters and geriatric assessment to predict overall survival in addition to clinical information in older patients with cancer. <i>Cancer</i> , 2018, 124, 3764-3775.	4.1	11
111	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , 2020, 38, 1096-1107.	2.6	11
112	Fatal pulmonary toxicity by the association of radiotherapy and medroxyprogesterone acetate. <i>Cancer</i> , 1985, 56, 2434-2436.	4.1	10
113	Final Overall Results of a Study with a Novel Triplet Induction Chemotherapy Regimen (PACCAGE) Followed by Consolidation Radiotherapy in Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2009, 4, 728-735.	1.1	10
114	Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. <i>Lung Cancer</i> , 2015, 90, 167-174.	2.0	10
115	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 607-615.	2.5	10
116	Metastatic Adenocarcinoma of the Lung in a 27-Year-Old Pregnant Woman. <i>Journal of Thoracic Oncology</i> , 2007, 2, 450-452.	1.1	9
117	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2007, 56, 247-254.	2.0	9
118	Unidentified cachexia patients in the oncologic setting: Cachexia UFOs do exist. <i>Nutrition</i> , 2019, 63-64, 200-204.	2.4	9
119	Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector. <i>BMC Research Notes</i> , 2018, 11, 751.	1.4	8
120	Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. <i>Oncotarget</i> , 2015, 6, 20132-20144.	1.8	8
121	The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. <i>Translational Lung Cancer Research</i> , 2018, 7, S134-S137.	2.8	7
122	High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer. <i>European Journal of Cancer</i> , 2003, 39, 346-352.	2.8	6
123	Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007, 619, 104-112.	1.0	6
124	Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer. <i>Oncogene</i> , 2015, 34, 1650-1657.	5.9	6
125	Breast cancer risk is increased in the years following false-positive breast cancer screening. <i>European Journal of Cancer Prevention</i> , 2017, 26, 396-403.	1.3	6
126	CONTAMINANTS WITHIN BACTERIAL PLASMID PREPARATIONS TRIGGER APOPTOSIS IN LIPOSOME TRANSFECTED OVCA3, BUT NOT IN SKOV3 OR AZ224 HUMAN OVARIAN CANCER CELLS. <i>Cell Biology International</i> , 2001, 25, 715-723.	3.0	5

#	ARTICLE	IF	CITATIONS
127	BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. <i>Neoplasma</i> , 2011, 58, 198-204.	1.6	5
128	Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). <i>Journal of Chemotherapy</i> , 2013, 25, 239-246.	1.5	5
129	Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer. <i>Breast Journal</i> , 2019, 25, 663-666.	1.0	4
130	Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth. <i>Frontiers in Immunology</i> , 2021, 12, 772555.	4.8	4
131	BRCA 1/2 Gene Mutation Testing-based Cancer Prevention and the Moral Concerns of Different Types of Patients. <i>Annals of the New York Academy of Sciences</i> , 1999, 889, 240-243.	3.8	3
132	About the c.156_157insAlu BRCA2 breast cancer predisposing mutation. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 621-622.	2.5	3
133	406 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 129.	2.2	3
134	Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?. <i>Translational Lung Cancer Research</i> , 2020, 9, 1-3.	2.8	3
135	Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 635.	4.1	3
136	The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	3
137	Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5		
138	Ethical Aspects of Genetic Counseling in Familial Breast and Ovarian Cancer.. <i>Annals of the New York Academy of Sciences</i> , 1997, 833, 170-172.	3.8	2
139	Characterization of Permanent Cell Lines That Contain the AAV2 <i><i>rep-cap</i></i> Genes on an Epstein-Barr-Virus-Based Episomal Plasmid. <i>Intervirology</i> , 2001, 44, 255-263.	2.8	2
140	Mutanome Engineered RNA Immunotherapy (MERIT). <i>Human Gene Therapy Clinical Development</i> , 2015, 26, 84-86.	3.1	2
141	What clinical factors influence advanced <i><i>BRCA1/2</i></i> mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?. <i>Journal of Clinical Oncology</i> , 2015, 33, 5546-5546.	1.6	2
142	Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial. <i>Cancer Research</i> , 2016, 76, CT020-CT020.	0.9	2
143	Effect of Neck Position During Radionuclide Superior Cavography. <i>Clinical Nuclear Medicine</i> , 1983, 8, 424-426.	1.3	1
144	Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer. <i>Breast Journal</i> , 2018, 24, 695-697.	1.0	1

#	ARTICLE	IF	CITATIONS
145	The effect of a varied exercise program (VEP) on shoulder function and lymphedema (LE) in breast cancer survivors (BCs): A pilot study.. Journal of Clinical Oncology, 2012, 30, 82-82.	1.6	1
146	Characterization of ovarian cancer long-term responders on olaparib.. Journal of Clinical Oncology, 2014, 32, 5534-5534.	1.6	1
147	The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.. Journal of Clinical Oncology, 2016, 34, 143-143.	1.6	1
148	Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project. , 2015, , .		1
149	Targeting polo-like kinase 1 and TRAIL to enhance apoptosis in non-small cell lung cancer (NSCLC) cells.. Journal of Clinical Oncology, 2017, 35, e14104-e14104.	1.6	1
150	Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation. Polish Archives of Internal Medicine, 2018, 128, 386-388.	0.4	1
151	Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?. Translational Lung Cancer Research, 2012, 1, 152-4.	2.8	1
152	Unusual Nonimmunoglobulin-Containing Inclusions in a Case of Follicular Large Cell Lymphoma. Ultrastructural Pathology, 1985, 8, 71-82.	0.9	0
153	P102 Adjuvant high-dose medroxyprogesterone acetate (HD-MPA) for early breast cancer. 13 years update of a multicenter randomized trial. European Journal of Cancer, 1998, 34, S40.	2.8	0
154	Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. Cancer Detection and Prevention, 2003, 27, 380-388.	2.1	0
155	P-570 Triplet induction chemotherapy followed by radiotherapy in inoperable stage III non small cell lung cancer (NSCLC). A phase II report. Lung Cancer, 2005, 49, S268.	2.0	0
156	450 A Belgian multicenter phase II randomized trial in HER2-negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with sunitinib after objective response to taxane-based chemotherapy. European Journal of Cancer, Supplement, 2010, 8, 190.	2.2	0
157	P3.05-005 Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1415.	1.1	0
158	The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results.. Journal of Clinical Oncology, 2012, 30, 9035-9035.	1.6	0
159	Impact of an interventional counseling procedure in BRCA families: Efficacy and safety.. Journal of Clinical Oncology, 2014, 32, 1552-1552.	1.6	0
160	Frequent <i>BRCA1/2</i> and <i>BARD1</i> germline mutations in triple-negative breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 1107-1107.	1.6	0
161	Abstract P1-12-11: Prospective study of aromatase inhibitor-induced bone loss and lipid levels in early hormone sensitive breast cancer treated with AI during 8 years. , 2015, , .		0
162	Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.. Journal of Clinical Oncology, 2015, 33, e11600-e11600.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.. Journal of Clinical Oncology, 2016, 34, 247-247.	1.6	0
164	A lung cancer-derived CRAF mutation to activate ERK pathway and to predict sensitivity to LY3009120 and trametinib.. Journal of Clinical Oncology, 2017, 35, e23197-e23197.	1.6	0
165	Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer.. Journal of Clinical Oncology, 2017, 35, e23154-e23154.	1.6	0
166	Abstract P3-02-05: Assessment of repeatability and uptake quantification of 68GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer. Cancer Research, 2022, 82, P3-02-05-P3-02-05.	0.9	0